Literature DB >> 9678304

Role of vasoactive mediators in primary and secondary pulmonary hypertension.

G Mikhail1, A H Chester, J S Gibbs, J A Borland, N R Banner, M H Yacoub.   

Abstract

The role of vasoactive mediators, such as endothelin-1, nitric oxide, prostacyclin, and thromboxane, in pulmonary hypertension remains undefined. This study investigated the circulating levels and transpulmonary gradients of these vasoactive mediators in patients with primary and secondary pulmonary hypertension to define whether there is increased production or decreased clearance of these substances in the lung vasculature.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9678304     DOI： 10.1016/s0002-9149(98)00296-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  7 in total

1.  Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity.

Authors:  Debbie Friedman; Jacqueline Szmuszkovicz; Miklos Rabai; Jon A Detterich; Jondavid Menteer; John C Wood
Journal:  J Heart Lung Transplant       Date:  2012-03-21       Impact factor: 10.247

Review 2.  Current management of patients with pulmonary hypertension and right ventricular insufficiency.

Authors:  S R Hankins; E M Horn
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

3.  Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease.

Authors:  S C Apostolopoulou; S Rammos; Z S Kyriakides; D J Webb; N R Johnston; D V Cokkinos; D Th Kremastinos
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

4.  Cyp2c44 gene disruption exacerbated pulmonary hypertension and heart failure in female but not male mice.

Authors:  Sachindra Raj Joshi; Anand Lakhkar; Vidhi Dhagia; Ariadne L Zias; Vasiliki Soldatos; Kaori Oshima; Houli Jiang; Katherine Gotlinger; Jorge H Capdevila; Michal L Schwartzman; Ivan F McMurtry; Sachin A Gupte
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

5.  Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide.

Authors:  Vera von Dossow; Claudia Spies; Hannes Schenk; Sabine Schlesinger; Christian von Heymann
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 6.  Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Respir Res       Date:  2009-10-13

7.  Deciphering the genetic and modular connections between coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart disease.

Authors:  Ye Yuan; Yingying Zhang; Xiaoxu Zhang; Yanan Yu; Bing Li; Pengqian Wang; Haixia Li; Yijun Zhao; Chunti Shen; Zhong Wang
Journal:  Mol Med Rep       Date:  2016-05-18       Impact factor: 2.952
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.